Rheumatoid Pain Relief Arthritis Drug Linked to Lymphoma Cancer For people with rheumatoid arthritis, methotrexate is the treatment of choice in reducing pain and inflammation. But there’s evidence the Pain Relief Arthritis Drug can activate a virus that can increase the risk of Lymphoma Cancer and similar cancers in some patients.The study appears in this month’s issue of the Journal of the National CancerInstitute.A number of reports have linked Pain Relief Arthritis Drug methotrexate with lymphoma and similar cancers of the lymph glands, says senior researcher Shannon C. Kenney,
MD, a microbiologist and infectious disease specialist with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Also, studies have shown that when rheumatoid arthritis patients quit taking methotrexate, their lymphoma went into regression, another sign that the Pain Relief Arthritis Drug directly contributes to the Lymphoma Cancer, she tells WebMD.
Some studies have indicated that the Pain Relief Arthritis drug’s immune-weakening effect places people at risk for viral-associated lymphomas.Another factor in this story: Epstein-Barr virus (EBV), a herpes virus that is common among adults.
Methotrexate and Lymphoma Cancer In a series of laboratory tests involving cells with latent EBV virus, Kenney found that using methotrexate on cells that contained the latent Epstein-Barr virus activated the virus, causing an increase in the release of infectious EBV.“An infectious form of the virus was released from the cells,” she tells WebMD. “We were surprised by that. We had already shown that certain kinds of chemotherapy could induce release of a form of EBV, but none would allow the infectious virus to be released.
she reports. Patients taking methotrexate had significantly higher EBV viral loads in their blood than patients taking other immune weakening Pain Relief Arthritis Drugs.With methotrexate, it’s different. “Methotrexate activates cells with the Epstein-Barr virus, but it doesn’t prevent replication of the [virus]. So it spews out the virus in an infectious form,” she explains.Similar results were found with polymyositis patients. However, the pattern was not found with Wegener granulomatosis — just as few Lymphoma Cancer have been reported in these patients, she notes.The data shows that methotrexate has a “unique ability” to trigger Epstein-Barr virus while also suppressing the immune system — thereby triggering Lymphoma Cancer in these patients, she adds. What’s Going On? Scientists once thought that — because methotrexate suppresses the immune system — the body has difficulty eliminating the Epstein-Barr virus, Kenney explains.
“There’s no question that the immune-suppressing ability of methotrexate is important for allowing EBV lymphomas to grow,” she tells WebMD.But why are EBV lymphomas so closely tied with methotrexate? The lymphomas likely arise because “a combination of bad things is happening,” she explains. “The immune system is suppressed and unable to handle the increasing amount of EBV in the blood.Why do some patients get Lymphoma Cancer? “I’m not sure,” says Kenney. Research shows that rheumatoid arthritis patients have been shown to have higher levels of Epstein-Barr virus in their blood, and their T cells don’t control EBV very well.
T cells help rid the body of cells that have been infected by viruses as well as cells that have been transformed into Lymphoma Cancer.Another recent study showed that antibodies, which can help diagnose rheumatoid arthritis called rheumatoid factor, can also reactivate EBV.A cautionary note: “These Lymphoma Cancer cases are rare among methotrexate takers,” Kenney tells WebMD.“We want to emphasize that fewer than 1 in 1,000 patients per year who get methotrexate who have rheumatoid arthritis get EBV lymphoma. It’s a very low-risk situation. We do not recommend that people stop taking methotrexate.